Quick Read – LLY’s FDA-cleared oral GLP-1 Foundayo drove 55.5% Q1 revenue growth, supporting a BUY rating with a $1,365 price target. – Novo Nordisk’s sales fell 4% with a 50% Wegovy price cut looming, while Merck posted just 5% growth, underscoring LLY’s competitive edge. – Act…
w: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Eli Lilly didn’t make the cut. Grab the names FREE today
Eli Lilly (NYSE:LLY) has accelerated despite its $1 trillion scale. Revenue grew 55.5% in Q1 2026, management raised full-year guidance by $2 billion, and the FDA cleared Foundayo, the first any-time-of-day oral GLP-1. Our 24/7 Wall St. price target for Eli Lilly is $1,365.51, implying roughly 15% upside from the current $1,186.85.
We rate LLY a buy with high (90%) confidence. 24/7 Wall St. Price Target Summary Foundayo Reset the Growth Story LLY is up 8.59% year-to-date and 50.84% over the trailing year, recovering from an April low of $903.99. Q1 2026 delivered $19.80 billion in revenue, beating the $17.80 billion consensus, with non-GAAP EPS of $8.55 versus the $6.79 estimate.